IMRIS, Inc. (IMRS) was a big mover last session, as the company saw its shares rise nearly 18% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company, as the stock is now down over 10% in the past one-month time frame.
This medical instrument company saw one positive estimate revision in the last 30 days. Its Zacks Consensus Estimate also moved higher over the same period, implying more solid trading potential for IMRIS. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
IMRIS currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Other stocks worth considering in the MedTech sector include Natus Medical Inc. (BABY), AngioDynamics Inc. (ANGO) and CryoLife Inc. (CRY). While Natus Medical holds a Zacks Rank #1 (Strong Buy), AngioDynamics and CryoLife carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment